Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pneumococcal protein vaccine (PPrV)
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PPrV is an investigational trivalent recombinant protein subunit vaccine designed to provide serotype-independent protection against *Streptococcus pneumoniae* infections. Developed by the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) in collaboration with Johns Hopkins University, the vaccine contains three conserved pneumococcal protein antigens: pneumococcal choline-binding protein A (PcpA), pneumococcal histidine triad protein D (PhtD), and a pneumolysin derivative (PlyD1). Unlike traditional polysaccharide or conjugate vaccines that target specific capsular serotypes, PPrV targets proteins common across various strains, potentially offering broader coverage. It is formulated with an aluminum hydroxide adjuvant and administered via intramuscular injection.
- Other names
- Trivalent pneumococcal protein vaccineICDDR,B pneumococcal vaccinePcpA + PhtD + PlyD1 vaccine
02
Targets
Ply (Pneumolysin)PhtD (Pneumococcal histidine triad protein D)PcpA (Pneumococcal choline-binding protein A)
Beyond the preview
Go deeper on Pneumococcal protein vaccine (PPrV).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pneumococcal protein vaccine (PPrV).